STADA Arzneimittel AG has been announced as the latest partner of Eintracht Frankfurt, who will help advertise the company’s nutritional supplement Elotrans reload. In the Eagles’ competitive opener on Sunday 13 August – at 1. FC Lokomotive Leipzig in the DFB Cup first round – the black away shirt will bear the Elotrans reload logo on its left sleeve. The agreement with the Bad Vilbel-based pharmaceutical manufacturer covers the men’s and women’s teams, Eintracht’s U21 regional league side, the club’s youth teams and the esports department as well as every competition. The deal runs until 30 June 2025 with the option of a one-year extension.
We’re really pleased to have gained a strong partner in STADA.
Axel Hellmann, CEO of Eintracht Frankfurt Fußball AG
Axel Hellmann, CEO of Eintracht Frankfurt Fußball AG: “We’re really pleased to have gained a strong partner in STADA, where everything is a good fit: the product advertised on our sleeve, the company’s tradition and bond with a location that boasts a strong international outlook, and the ambition of healthy, powerful growth.”
The partnership with Eintracht Frankfurt is an excellent strategic fit for Elotrans reload and will accelerate its success.
Peter Goldschmidt, CEO and global chairman of STADA
Peter Goldschmidt, CEO and global chairman of STADA: “Consumer healthcare has become STADA’s largest business segment. Growth products like Elotrans reload will help us consolidate number one spot in Germany. The partnership with Eintracht Frankfurt is an excellent strategic fit for Elotrans reload and will accelerate its success.”
Elotrans supports body vitalisation
STADA recently expanded its portfolio of electrolyte products with Elotrans reload, adding a nutritional supplement to the Elotrans umbrella brand which supports the vitalisation of the body. Elotrans reload comes in a pleasant orange taste, is vegan-friendly and does not contain gluten, lactose or preservatives.
About STADA Arzneimittel AG
STADA Arzneimittel AG is based in Bad Vilbel, Hesse. The company focuses on a three-pillar strategy consisting of consumer healthcare products, generics and special types of pharmaceuticals. STADA Arzneimittel AG’s products are sold in 120 countries worldwide. In the fiscal year of 2022, STADA achieved sales of €3,797.2m as well as €884.7m in earnings before interest, taxes, depreciation and amortisation. On 31 December 2022, STADA employed 13,183 people worldwide.